1 min read

Shortening Development and Approval Timelines for Novel Medicinal Products

The FDA and EMA offer expedited regulatory approval pathways to accelerate time-to-market for novel therapies intended to treat serious conditions and unmet medical needs. There are twelve special designations, many of which reduce clinical development and approval timelines. However, these are not always granted.

In this infographic, Veristat regulatory experts highlight the benefits of, qualifying criteriaDownload the Infographic for, and timing and procedures for twelve expedited programs and designations. Companies must build a strategic regulatory plan and leverage the right pathways to ensure a seamless regulatory strategy and submission plan for both U.S. and global registrations. Overall, these expedited regulatory pathways can save time and reduce the cost of bringing therapies to market—and to patients—sooner.

Download the infographic to learn more about the benefits of these key special designations:

  • Orphan Drug Designation
  • Breakthrough Therapy (BT)
  • PRIority MEdicines (PRIME)
  • Fast Track (FT)
  • Qualified Infectious Disease Product Designation (QIDP)
  • Regenerative Medicine Advanced Therapy (RMAT)
  • Priority Review (PR)
  • Accelerated Approval
  • Emergency Use Authorization (EUA)
  • Accelerated Assessment (AA)
  • Conditional Marketing Authorization (CMA)
  • Real Time Oncology Review (RTOR)

DOWNLOAD

 

Screen Shot 2022-11-05 at 12.20.20 PM

 

Meet Veristat. Learn More.


 

4 min read

Plenary Session Presentation: Putting Science First in Rare Disease Studies

Don´t miss Veristat’s plenary presentation at the World Orphan Drug Congress (WODC), Boston, Thursday, April 25th at...

1 min read

Swiss Biotech Day

Meet Veristat in Basel at the Swiss Biotech Day, 22-23 April 2024 

With nearly 30 years of experience in clinical trial...